Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

Some New York doctors are working on new ways to treat advanced cancers. Chimeric Antigen Receptor, or CAR, T-cell therapy treats certain blood cancers by genetically modifying a person’s T-cells to ...

Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...

The Penn physician-researcher has received more funding to advance his 'Trojan horse' for attacking gastroesophageal cancer.